Ieq Capital LLC Acquires New Position in Illumina, Inc. $ILMN

Posted by Stanley Muller on Aug 22nd, 2026

Ieq Capital LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 267,932 shares of the life sciences company’s stock, valued at approximately $47,111,000.

Other hedge funds have also added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new position in shares of Illumina during the fourth quarter worth approximately $25,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. Laurel Wealth Advisors LLC bought a new position in Illumina in the fourth quarter worth approximately $26,000. Activest Wealth Management grew its stake in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new position in Illumina during the 2nd quarter worth $32,000. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 2,095,958 shares of company stock valued at $401,720,974. Company insiders own 2.90% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $219.40 on Friday. The firm has a 50 day moving average of $188.01 and a 200 day moving average of $152.44. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.43.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the firm earned $1.19 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on ILMN. Royal Bank Of Canada lifted their target price on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their price target on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Thursday, May 14th. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $188.40.

Check Out Our Latest Analysis on Illumina

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.